Laronidase Completed Phase 3 Trials for Mucopolysaccharidosis V / Type 1 Mucopolysaccharidosis / Hurler-Scheie Syndrome / Hurlers Syndrome Treatment

Indications	Status	Purpose	Phase
DBCOND0008371 (Mucopolysaccharidosis V) DBCOND0020490 (Type 1 Mucopolysaccharidosis) DBCOND0031271 (Hurler-Scheie Syndrome) DBCOND0043682 (Hurlers Syndrome)	Completed	Treatment	3

clinicaltrials.gov Identifier	Title	Drugs
NCT00146770	Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients	Laronidase (DB00090)
NCT00258011	Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease	Laronidase (DB00090)